Luttringer Olivier, Theil Frank-Peter, Poulin Patrick, Schmitt-Hoffmann Anne H, Guentert Theodor Walter, Lavé Thierry
F. Hoffmann-La Roche Ltd., Pharma Research, Department of Non-Clinical Drug Safety, CH-4070 Basel, Switzerland.
J Pharm Sci. 2003 Oct;92(10):1990-2007. doi: 10.1002/jps.10461.
The objective of this study was to use in synergy physiologically based and empirical approaches to estimate the drug-specific input parameters of PBPK models of disposition to simulate the plasma concentration-time profile of epiroprim in human. The estimated input parameters were the tissue:plasma partition coefficients (Pt:p) for distribution and the blood clearance (CL) for the in vivo conditions. Epiroprim represents a challenge for such methods, because it shows large interspecies differences in its pharmacokinetic properties. Two approaches were used to predict the human Pt:p values: the tissue composition model (TCM) and the "Arundel approach" based on the volume of distribution at steady state (Vdss) determined in vivo in the rat. CL in human was predicted by (1) conventional allometric scaling of in vivo animal clearances (CAS), (2) physiologically based direct scaling up of in vitro hepatocyte data (DSU), and (3) allometric scaling of animal intrinsic in vivo blood CL normalized by the ratios of animal:human intrinsic clearances determined in vitro with hepatocytes (NAS). The performance of prediction was assessed by comparing separately the above pharmacokinetic parameters (Vdss estimated from the Pt:p values and blood CL) with the corresponding in vivo data obtained from the plasma kinetic profiles. These input parameters were used in PBPK models, and the resulting plasma concentration-time profiles of epiroprim were compared with those observed in rat and human. Previously to the construction of the human PBPK model, a model for the rat was also developed to gain more confidence on the model structure and assumptions. Overall, using the TCM and the NAS for the parameterization of the distribution and clearance, respectively, the PBPK model gave the more accurate predictions of epiroprim's disposition in human. This study represents therefore an attractive approach, which may potentially help the clinical candidate selection.
本研究的目的是协同使用基于生理学和经验性的方法,来估计处置的生理药代动力学(PBPK)模型的药物特异性输入参数,以模拟人血浆中依匹罗prim浓度-时间曲线。估计的输入参数为体内分布的组织:血浆分配系数(Pt:p)和血液清除率(CL)。依匹罗prim对这些方法而言是一项挑战,因为其药代动力学特性存在较大的种间差异。采用两种方法预测人Pt:p值:组织组成模型(TCM)和基于大鼠体内稳态分布容积(Vdss)的“Arundel方法”。通过以下方法预测人CL:(1)体内动物清除率的传统异速生长标度法(CAS),(2)基于体外肝细胞数据的生理学直接放大法(DSU),以及(3)通过体外肝细胞测定的动物:人固有清除率之比归一化的动物体内固有血液CL的异速生长标度法(NAS)。通过分别将上述药代动力学参数(由Pt:p值估算的Vdss和血液CL)与从血浆动力学曲线获得的相应体内数据进行比较,评估预测性能。将这些输入参数用于PBPK模型,并将依匹罗prim所得的血浆浓度-时间曲线与在大鼠和人中观察到的曲线进行比较。在构建人PBPK模型之前,还开发了大鼠模型,以增强对模型结构和假设的信心。总体而言,分别使用TCM和NAS对分布和清除率进行参数化,PBPK模型对依匹罗prim在人体内处置的预测更为准确。因此,本研究代表了一种有吸引力的方法,可能有助于临床候选药物的选择。